TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00715559
Drug: cysteamine bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
Study: NCT00604825
Drug: Other: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00616551
Drug: C2L-OCT-01 PR, 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by deep IM injection (gluteus) on days 1 and 42
Study: NCT00133809
Drug: Transplantation of Human Islets
Normalized name: microspheres of human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
Study: NCT03205150
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
Study: NCT03205150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
Study: NCT00675987
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 po QD
Study: NCT03714763
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
Study: NCT02182310
Drug: BI 201335 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01451398
Drug: Technosphere® Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Insulin Inhalation Powder
Study: NCT01451398
Drug: Technosphere Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT03430180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Study: NCT00305682
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
Study: NCT00065468
Drug: CCI-779
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of CCI-779 given Intra Venously once per week
Study: NCT04047004
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
Study: NCT01874574
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Study: NCT01874574
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
Study: NCT04349410
Drug: Hydroxychloroquine, Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTVDM Planar, SPECT, PET
Study: NCT03028467
Drug: GSK3196165 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study: NCT04349410
Drug: Hydroxychloroquine, Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTVDM Planar, SPECT, PET
Study: NCT03028467
Drug: GSK3196165 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study: NCT04349410
Drug: Hydroxychloroquine, Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTVDM Planar, SPECT, PET
Study: NCT04349410
Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTVDM Planar, SPECT, PET
Study: NCT04349410
Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMTVDM Planar, SPECT, PET
Study: NCT03028467
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.
Study: NCT00307099
Drug: Standard antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous antibiotic therapy for a minimum of 8 days.
Study: NCT01648179
Drug: GSK1322322 (mesylate salt) Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
Study: NCT01648179
Drug: GSK1322322 (freebase) tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
Study: NCT01648179
Drug: GSK1322322 (mesylate salt) Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
Study: NCT01648179
Drug: GSK1322322 (freebase) tablets FED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
Study: NCT03028467
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid tablet 5 mg per week is given orally.
Study: NCT05926128
Drug: Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
Study: NCT02749695
Drug: Melsmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
Study: NCT02525718
Drug: 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.
Study: NCT00012324
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03395977
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose placebo for pills and saline for perfusion.
Study: NCT02588105
Drug: AZD0156
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
Study: NCT02588105
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Module 2 combination with irinotecan/FOLFIRI
Study: NCT00377637
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3.
Study: NCT00377637
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
Study: NCT00377637
Drug: Placebo to Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo capsules matching Azathioprine taken orally once a day.
Study: NCT00377637
Drug: Placebo to Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
Study: NCT00377637
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
Study: NCT01796028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01796028
Drug: TAXOTERE®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02942004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
Study: NCT03186053
Drug: sodium creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium creatine phosphate .Loading dose followed by continuous infusion in operation
Study: NCT01620268
Drug: Leflunomide and orotic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
Study: NCT02754739
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
Study: NCT02922153
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institutional SOC for pain management will be followed.
Study: NCT00334425
Drug: MENOPUR; GONAL-F
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04475848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg.
Study: NCT04616872
Drug: Methotrexate-LDE
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
Study: NCT04616872
Drug: Placebo-LDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
Study: NCT00133562
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02380924
Drug: DSP loaded RBC using EryDex System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Study: NCT02380924
Drug: Sham treated RBC using the EryDex System
Normalized name: ANTICOAGULANT CPDA-1 THE CLX SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
Study: NCT00399191
Drug: stable isotope of iron, dysprosium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00687687
Drug: BSI-201 (Iniparib)
Normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
Study: NCT02334982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-137 placebo-matching tablets
Study: NCT00480402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a Placebo
Study: NCT04341402
Drug: Antifungal Nail Gel Study
Normalized name: urea Topical Gel [Kera Nail]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
Study: NCT00472810
Drug: MMC in glaucoma filtering surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Study: NCT02630108
Drug: EADM
Normalized name: ALCOHOL 69 mL in 100 mL TOPICAL GEL [Treadmill Doctor Advanced Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
Study: NCT02154464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004444
Drug: paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004444
Drug: streptomycin
Normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00962312
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02224625
Drug: 2% CHG Cloth solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational CHG
Study: NCT03017820
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00736905
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04465500
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
Study: NCT03719430
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
Study: NCT00229437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
Study: NCT00377442
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg po
Study: NCT00162448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, Single dose, 1 day.
Study: NCT00249873
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (tablets)
Study: NCT01756989
Drug: Thalidomide, etoposide, celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day.
Study: NCT01164202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 3cps/days 4 weeks over 6 during 1 year
Study: NCT00958854
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03555487
Drug: 18F-choline PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
Study: NCT00555789
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg oral b.i.d.
Study: NCT00555789
Drug: mycophenolic plus tacrolimus
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 720mg b.i.d. 2yrs
Study: NCT03098680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group descriptions
Study: NCT00543218
Drug: calcitonin 100 IU/day subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05364918
Drug: Jeksung combined with anti-radiation spray
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat radiation stomatitis with Jeksung combined with anti-radiation spray
Study: NCT03011866
Drug: Wound topically irrigated with 500mg TXA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03011866
Drug: 1mg/kg/hr TXA intravenous infusion till the last suture
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02306889
Drug: ANTARA® (fenofibrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130mg Capsules
Study: NCT02254850
Drug: Mesoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
Study: NCT02254850
Drug: Mesoglycan
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
Study: NCT01816321
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
Study: NCT01816321
Drug: hp HMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
Study: NCT02254850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
Study: NCT01232790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00468585
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03592888
Drug: mDC3/8-KRAS Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
Study: NCT02310074
Drug: Pulsatile Gonadotropin Releasing Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02310074
Drug: Urinary Follicle-Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Follicle-Stimulating Hormone (uFSH)
Study: NCT02945826
Drug: One injection of 68Ga-NOTA-AE105
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 68Ga-NOTA-AE105
Study: NCT01477762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet will be taken ten hours prior to completing study assessments.
Study: NCT02254850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
Study: NCT00313846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
Study: NCT03508102
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
Study: NCT01800045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule in the morning before breakfast
Study: NCT04141579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00457613
Drug: bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03070314
Drug: Echinaforce junior
Normalized name: Disprol Junior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea Purpurea Extract Pill, sweetened and with orange flavour
Study: NCT02838225
Drug: Docetaxel, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02838225
Drug: Docetaxel, Doxorubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03693599
Drug: Syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
Study: NCT00730275
Drug: Comparator: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.